Almirall S.A

Feb 19, 2024 | money.mymotherlode.com | Almirall S.A

Almirall obtains exclusive global rights to develop and commercialize NN-8828 for use in several fields, including immune inflammatory dermatological diseases NN-8828 is an IL-21 blocker which inhibits the pathophysiological functions induced by this cytokine in several immune-modulated diseases Almirall S.A. (BME: ALM), a global pharmaceutical company dedicated to medical dermatology, announced today that it has entered into an exclusive license agreement with Novo Nordisk for rights to the...

Nov 17, 2023 | money.mymotherlode.com | Almirall S.A

Lebrikizumab is a monoclonal antibody that binds to IL-13 with high affinity, selectively inhibiting its downstream signalling1-4 Following the European Commission approval, Germany is the first country where lebrikizumab will be available for prescription Lebrikizumab demonstrated early clinical efficacy and maintenance of response up to 2 years in both monotherapy and combination with topical corticosteroids5-8 with monthly maintenance dosing for all patients13 Almirall S.A. (BME: ALM), a...

Nov 14, 2023 | money.mymotherlode.com | Almirall S.A

The collaboration expands Absci’s de novo AI drug creation portfolio into dermatology and accelerates discovery for broader chronic inflammatory diseasesAlmirall S.A. (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced a drug discovery partnership aimed to develop and commercialize AI-designed therapeutics to fight chronic and debilitating dermatological diseases.

Nov 13, 2023 | jofskin.org | Eric Simpson |Melinda Gooderham |Almirall S.A

Article Details How to Cite Guttman-Yassky, E. ., Weidinger, S. ., Simpson, E. ., Gooderham, M. ., Irvine, A. ., Spelman, L. ., Silverberg, J. ., Elmaraghy, H. ., DeLuca-Carter, L. ., Buziqui Piruzeli, M. L. ., Hu, C. ., Yang, F. E. ., Pierce, E. ., Bardolet, L. ., & Thaci, D. . (2023).

Nov 9, 2023 | money.mymotherlode.com | Almirall S.A

Almirall achieves Net Sales growth of 6.4%, driven by strong European dermatology performance Almirall's European Dermatology business continued to be the driving force behind Almirall's strong performance in the first nine months of 2023, with a growth rate of 15.9% underpinned by the success of Ilumetri® and other recently launched products Good performance of Key products in Europe: strong year-on-year growth of Ilumetri® (psoriasis) across geographies; Wynzora® (psoriasis) sales gaining...